tyrosine kinase c-Abl inhibitors

http://www.mattasons.com/parkinson%E...report/334005/

When we blocked tyrosine kinase c-Abl activation, parkin function was preserved and neurons were spared,” Dr. Imam said. “We believe these studies provide sound rationale for moving forward with a preclinical trial of tyrosine kinase c-Abl inhibitors, with the goal of developing a potent therapeutic drug for slowing the progression of Parkinson’s.”

If preclinical trials in animal models of Parkinson’s disease yield positive results, the next step would be clinical trials in human patients, Dr. Imam said.

Tyrosine kinase c-Abl inhibitors are approved by the FDA for treating myeloid leukemia and gastrointestinal tumors. This could speed approval of the drug for Parkinson’s and its translation from bench research to clinical practice.